ERBB2 and gastric cancer: Nearly half the patients with metastatic HER2-positive GC experience disease progression or death after trastuzumab treatment, and the mechanisms of drug resistance are relatively complex and uncertain (Bang et al., 2010; Valabrega et al., 2007).